Post-Approval Biotech: First 90 Days After FDA Approval

The FDA approval hits the tape at 4:02 PM. The stock spikes 25% in after-hours trading. You own shares and you’re celebrating.

Here’s what you should actually be doing. FDA approval is not the finish line. It’s the starting line of a completely different race. The 90 days after approval determine whether a drug becomes a commercial success or a $2 billion write-down. Most biotech investors don’t track any of the four milestones that actually matter.

The 90-Day Timeline

Every biotech drug launch follows the same pattern. Pre-approval run-up, approval-day pop, then a quiet 30-45 day drift while the market waits for the first real commercial data. The consensus revenue model for the next two years gets built in this window. Miss the numbers and the stock drops 15-30%, even though it’s “just the first month.”

Day 1-7: The Label Is Everything

The FDA approval letter is public within 24 hours. Read the actual label on Drugs@FDA, not the press release. Compare what the FDA approved to what the company requested.

A narrower-than-expected label can gut the commercial opportunity before the drug ships its first vial. A restricted patient population cuts the addressable market. A boxed warning, the FDA’s most severe safety warning, appears as boxed text at the top of the label and imposes a permanent competitive disadvantage. A REMS requirement (Risk Evaluation and Mitigation Strategy) adds administrative burden that slows prescribing.

What this means in dollars: if a drug was projected for $2 billion in peak sales based on the requested label, and the FDA restricts it to a subgroup representing 40% of that population, peak sales drop to $800 million. The stock should reprice accordingly. For how to model those peak sales, see the biotech valuation guide.

Real example: Sarepta’s Elevidys was approved for Duchenne muscular dystrophy but the label restricted use to ambulatory patients under age 5. The broader DMD population the company targeted, roughly 3-4x larger, was excluded. The stock subsequently declined from its highs as the revenue math reset.

Day 7-30: Pricing and PBM Positioning

The company announces the wholesale acquisition cost (WAC), which is the manufacturer’s list price. Then the pharmacy benefit managers (PBMs) weigh in.

A price above $200,000 per year triggers formulary fights. PBMs control which drugs patients can access, and they negotiate hard on anything with a six-figure annual cost. Expect prior authorization requirements, step therapy (the patient must fail a cheaper drug first), and exclusion from preferred formulary tiers.

A price well below competitors doesn’t signal confidence. It signals the company knows its data is weaker. If your drug is better, you charge for it. If you undercut the market leader by 50%, the Street reads that as the company admitting inferiority.

The gross-to-net bubble matters here. The WAC is the list price, but the manufacturer’s realized net price runs 40-60% below WAC after rebates to PBMs, discounts to hospitals, and government-mandated concessions. A drug with a $200,000 WAC may net $80,000-120,000. Your revenue model needs to use net price, not WAC.

Check competing labels on DailyMed (dailymed.nlm.nih.gov) to compare approved labels, indications, and pricing benchmarks for drugs in the same therapeutic class.

Day 30-60: Distribution Buildout

Can the company actually get the drug to patients? This is where most small biotechs fail. They have a great drug and no infrastructure.

For infused drugs: How many infusion centers are signed up? An infused oncology drug needs contracts with community oncology practices and hospital systems. Each one takes 30-60 days to credential. If the company has 5 centers signed at launch, it can serve maybe 50 patients that quarter, not 500.

For oral drugs: Is the drug on pharmacy shelves? For specialty oral drugs, the pharmacy channel (specialty pharmacies, mail-order, retail chains) needs 4-8 weeks to stock and train.

For gene therapies: How many treatment centers are certified? Gene therapies require certified administration centers with trained staff. Bluebird bio’s Zynteglo, priced at $2.8 million, launched with fewer than 10 qualified treatment centers in the U.S. and never reached meaningful revenue. The price was right for the economics but wrong because no payer infrastructure existed to support it.

Red flag: The CEO talks about total addressable market on the earnings call but can’t name the number of signed infusion centers. If the answer is “we’re working on it,” the launch is behind schedule.

Day 60-90: First Prescription Data

IQVIA and Symphony Health publish weekly prescription data with a 2-3 week lag. These are the first real numbers that tell you whether the drug is being prescribed.

The first 4 weeks of scripts set the Street’s revenue model for the next two years. Analysts build quarterly estimates from the launch trajectory. A launch tracking 20% below consensus means every quarterly estimate for the next 6-8 quarters gets revised down. The stock drops accordingly, even though it’s “just the first month” of data.

What to watch: new patient starts per week (NRx), total prescriptions (TRx), refill rates. For infused drugs, look for new patient enrollment numbers in quarterly reports.

Red Flags in the First 90 Days

• CEO departs within 60 days of approval. This signals the board knows something the market doesn’t about commercial outlook. A CEO who just got a drug approved doesn’t leave voluntarily.
• Manufacturing issues delay launch. If the FDA approval came with manufacturing conditions or the company can’t produce at commercial scale, the launch window shrinks while competitors advance.
• No key account hires announced. A commercial launch needs a sales force. If the company hasn’t announced a VP of Commercial or key account directors by Day 45, the launch is under-resourced.
• Competitor launches a better-labeled product in the same window. A competing drug approved with a broader label or no boxed warning during your 90-day window resets competitive positioning before you’ve shipped your first dose.

The Stock Price Pattern

The pattern repeats across biotech approvals:

1. Pre-approval run-up (4-6 weeks before PDUFA): The stock climbs on anticipation. Buyers position for approval.
2. Approval day: Typically a 10-30% pop, occasionally a “sell the news” fade if approval was fully priced. For what happens before PDUFA, see the FDA catalyst trading guide.
3. Quiet drift (Days 1-45): The stock drifts as the market waits for commercial data. No news means no bid.
4. First script data (Days 60-90): The re-pricing event. A launch beating consensus by 20% can add 15-25%. A launch missing by 20% can subtract the same. The approval pop gets validated or reversed here.
5. Re-rating or disappointment: After first script data, the stock settles into a new range based on the launch trajectory. This becomes the base for the next catalyst: label expansion, competitor entry, or first full-quarter earnings.

Final Checklist

• Read the actual label on Drugs@FDA, not the company press release
• Compare approved indication to the requested indication: what was excluded?
• Check for boxed warnings, REMS requirements, or restricted populations
• Find the WAC announcement and compare to competitor pricing
• Calculate the net price (assume 40-60% below WAC)
• Verify commercial infrastructure: how many infusion centers, pharmacies, or treatment centers are signed?
• Set a calendar reminder for the first IQVIA/Symphony prescription data window (Day 60-90)
• Watch for CEO departure, manufacturing delays, or concurrent competitor launches

FDA approval is an event. Commercial launch is a process. The first 90 days tell you which one you actually own.